Information Provided By:
Fly News Breaks for June 12, 2018
STML
Jun 12, 2018 | 07:28 EDT
Roth Capital analyst Jotin Marango started Stemline with a Buy rating and $30 price target, stating that he expects the company to "sail smoothly through a BLA and then through M&A," given the strengths he sees for its lead asset SL-401, which is being investigated for an indication with no standard of care - front-line, blastic plasmacytoid dendritic cell neoplasm, or BPDCN.
News For STML From the Last 2 Days
There are no results for your query STML